UCB, Inc. v. Catalent Pharma Solutions, Inc.
JD Supra Law
JULY 30, 2021
RE38,551 (“the ’551 patent”) - Nature of the Case and Issue(s) Presented: The ’551 patent issued on July 6, 2004, and claimed “anticonvulsant enantiomeric amino acid derivatives,” including lacosamide. Catalent, a contract manufacturer, imported 479 kgs. UCB held the NDA for Vimpat. By: Robins Kaplan LLP
Let's personalize your content